In this regard, scaffolds based on assembled HIV p24 capsid (CA) proteins would, indeed, represent an invaluable advancement. In fact, besides the presentation of relevant Env-neutralizing epitopes, it may also provide Gag epitopes for the elicitation of HIV nonneutralizing protective antibodies, which have previously been shown to be associated with a more delayed disease progression (2, 8, 12, 16, 29, 34) . Furthermore, p24 is an abundant source of CD4 T-cell epitopes (3) , and the induction of CD4 ϩ T-helper-cell responses by scaffolds based on assembled HIV p24 CA proteins is highly probable.
In support of this approach, the ability of recombinant p24 capsid proteins to assemble in vitro, forming stable and soluble stand-alone nonenveloped capsomers without either cellular membranes or matrix (MA) or nucleocapsid (NC) Gag viral proteins, has recently been described (13, 22, 23) . Based on such observations, the HIV p24 CA protein is potentially a highly attractive molecule to be used as a particulate protein scaffold for presenting dense repetitive arrays of minimal structural and antigenic HIV Env epitopes aimed at eliciting broadly NAbs. Preliminary biocomputational analysis using the full Env V3 loop as proof of concept indicates that the HIV p24 CA protein has suitable acceptor sites for engrafting foreign epitopes without disrupting the formation of capsomer hexamer structures (Fig. 1) described by Ganser-Pornillos et al. (14) and that the V3 epitope does retain its antibody-bound conformation (Fig. 2) .
Such observations strongly support the theoretical possibility of developing a scaffolding strategy based on p24 CA proteins displaying conformationally minimal structural and antigenic HIV Env epitopes. Unlike other strategies described to date, this strategy would provide the relevant advantage of presenting not only the Env broadly neutralizing epitopes but also the Gag epitopes for eliciting HIV nonneutralizing protective antibodies (2, 12, 34) .
Studies to experimentally prove the efficacy of such a strategy are currently ongoing and are looking for a further approach to advance the efficacy of our global anti-HIV vaccine armamentarium.
